Cogent Biosciences (COGT) Total Current Liabilities (2017 - 2026)

Cogent Biosciences (COGT) has reported Total Current Liabilities for 10 consecutive years, with $58.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 17.57% year-over-year to $58.0 million; the TTM figure through Mar 2026 stood at $58.0 million (up 17.57% YoY), while the FY2025 annual figure was $64.0 million, up 14.8% from the prior year.
• Total Current Liabilities fell to $58.0 million in Q1 2026 per COGT's latest filing, from $64.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $64.0 million in Q4 2025 and bottomed at $17.9 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $40.8 million across 5 years, with a median of $38.2 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 116.93% — and 2023, when it declined 6.87%.
• Cogent Biosciences' Total Current Liabilities stood at $26.8 million in 2022, then surged by 42.16% to $38.2 million in 2023, then jumped by 45.96% to $55.7 million in 2024, then climbed by 14.8% to $64.0 million in 2025, then slipped by 9.34% to $58.0 million in 2026.
• Business Quant data shows COGT's Total Current Liabilities at $58.0 million in Q1 2026, $64.0 million in Q4 2025, and $62.2 million in Q3 2025.